Skin Boosters vs Dermal Fillers: What’s the Difference?
Skin boosters and dermal fillers can both involve hyaluronic acid, but they are not interchangeable product categories. Skin boosters are generally used with the primary objective of improving skin quality, hydration and tissue characteristics, while dermal fillers are selected for product-dependent volume, contour and structural correction.
For practitioners comparing skin boosters vs dermal fillers, the appropriate choice depends on the patient’s anatomy, clinical presentation, treatment objective, the formulation being considered and current manufacturer guidance.
This guide explains the distinction, compares the major skin-booster families and provides a practical framework for deciding when a skin-quality product or a structural filler may be more relevant.
Skin Boosters vs Dermal Fillers Comparison
| Feature | Skin boosters | Dermal fillers |
|---|---|---|
| Primary objective | Skin quality, hydration and product-dependent bio-remodelling or revitalisation | Product-dependent volume, contour and structural correction |
| Formulation | Varies widely: HA-based, amino-acid combinations and other injectable skin-quality formulations | Commonly cross-linked HA gels; other filler classes also exist |
| Placement | Product and indication dependent, often intradermal or subdermal | Product, anatomy and indication dependent across multiple tissue planes |
| Localised volume | Not usually the primary objective | Often a principal treatment objective |
| Selection | Based on skin-quality concern, formulation and patient assessment | Based on structural objective, anatomy, rheology/formulation and patient assessment |
Practitioners can compare the Longeva Pharma skin booster range and our professional dermal filler range.
What Defines a Skin Booster?
The term “skin booster” does not describe one single formulation. In aesthetic practice it is used across a broad group of injectable products intended primarily to improve aspects of skin quality rather than provide the localised structural augmentation associated with conventional volumising fillers.
That broad category is precisely why practitioners should assess the individual product rather than assume that every product marketed as a skin booster behaves in the same way.
What Are Dermal Fillers?
Conventional dermal fillers include products designed to provide product-dependent volume, contour or structural correction. Hyaluronic-acid fillers vary substantially in concentration, cross-linking, cohesivity, rheology and intended placement, so “dermal filler” is itself a category rather than a single treatment.
The practical distinction is therefore about treatment objective and individual formulation, not simply whether a product contains hyaluronic acid.
The Main Skin Booster Product Families
HA Bio-Remodelling and Hydration-Focused Formulations
HA-based skin-quality products can differ significantly in molecular structure, stabilisation and intended use. Profhilo is a well-known example of a thermally stabilised HA formulation used within a bio-remodelling approach, while Restylane Skinboosters use stabilised HA formulations intended for skin-quality indications.
For a detailed comparison of Profhilo and conventional fillers, see Profhilo vs Dermal Fillers.
Amino-Acid and HA Combination Products
Products such as Jalupro and Sunekos combine different formulation approaches with skin-quality objectives. Sunekos, for example, combines non-cross-linked hyaluronic acid with amino acids. These products should not simply be treated as softer versions of conventional cross-linked dermal filler.
Polynucleotides as an Adjacent Category
Polynucleotides occupy an adjacent skin-quality category and should be considered separately from both conventional HA skin boosters and dermal fillers. Formulations and intended uses vary, and practitioners should work from current product information and their own clinical assessment rather than category labels alone.
See our UK practitioner guide to polynucleotides and browse the polynucleotide range.
When Might a Skin Booster Be Considered?
A skin booster may be relevant where the primary treatment objective concerns skin quality rather than structural augmentation. Depending on the individual product and patient, this may include hydration, texture, fine superficial lines or broader skin-quality concerns.
The practitioner should assess the patient, identify the treatment objective and then select a formulation whose manufacturer information and intended use fit that objective.
When Might a Dermal Filler Be Considered?
A dermal filler may be more relevant where the treatment objective is localised volume, projection, contour or structural correction. The appropriate filler depends on the anatomical area, tissue characteristics, required behaviour of the product and the practitioner’s assessment and competence.
Dermal fillers should therefore not be positioned as simply a “stronger skin booster”, just as a skin booster should not be expected to provide the same structural effect as a volumising filler.
Can Skin Boosters and Dermal Fillers Be Used Together?
Potentially. They are not necessarily competing approaches because they can address different treatment objectives.
A patient may present with both skin-quality concerns and structural volume loss. Following appropriate assessment, different product categories may form part of a staged treatment plan. Treatment planning should take account of anatomy, previous injectable treatment, the individual formulations, manufacturer guidance and practitioner competence.
Each product should have a clearly defined purpose within the treatment plan rather than being added simply because the categories can be combined.
How Do Skin Boosters Differ From Polynucleotides?
The terms are sometimes used loosely in the market, but they should not be treated as synonyms. Polynucleotide formulations are distinct from conventional HA-based skin boosters, while products sold within the skin-booster category can themselves contain very different ingredients.
For practitioners using both modalities, our guide to sequencing polynucleotides with HA skin boosters provides further context.
Choosing by Treatment Goal
A systematic approach reduces over-reliance on brand familiarity. Before selecting a product, consider:
- Is the primary objective skin quality or structural correction?
- What does the patient’s anatomy and tissue presentation indicate?
- What is the individual product formulated and intended to do?
- What tissue plane and technique does the manufacturer recommend?
- What previous injectable treatments are present?
- Would a staged approach address separate objectives more clearly?
- Is the proposed treatment within the practitioner’s competence and appropriate for the patient?
Skin Booster Brands: Compare the Formulation, Not Just the Name
The UK skin-booster market includes multiple product families, including Profhilo, Restylane Skinboosters, Jalupro, Sunekos and other HA or combination formulations. The important point is that these products do not all share the same composition, mechanism or intended use.
Practitioners should therefore compare current manufacturer information, formulation, intended treatment objective and patient presentation rather than treating “skin booster” as a single standardised product type.
Storage, Handling and Product Information
Storage and handling requirements vary by product. Practitioners should follow the current manufacturer information and instructions supplied with the specific product rather than applying one storage rule to the entire skin-booster category.
Products should remain in appropriate packaging, be checked for integrity and expiry before use, and be handled in accordance with the applicable product instructions and clinic governance procedures.
Buying Considerations for a Clinic
For clinic procurement, avoid building a formulary around brand count alone. A more useful approach is to understand which treatment objectives each stocked product is intended to address and where products genuinely duplicate one another.
Practitioners can browse skin boosters, polynucleotides and dermal fillers through Longeva Pharma when comparing products appropriate to their clinical practice, always following current manufacturer guidance and working within professional scope and competence.
Frequently Asked Questions About Skin Boosters vs Dermal Fillers
Are skin boosters the same as dermal fillers?
No. Although some products in both categories contain hyaluronic acid, their formulations and primary treatment objectives can differ substantially. Skin boosters are generally focused on skin quality, while conventional dermal fillers are used for product-dependent volume, contour and structural correction.
Do skin boosters add volume like dermal fillers?
Localised structural volume is generally not the primary objective of a skin booster. Practitioners should check the individual formulation and manufacturer information rather than assume all products within the category behave identically.
What is the difference between skin boosters and fillers?
The key difference is usually the intended treatment objective and product behaviour. Skin boosters generally target skin quality; dermal fillers are commonly selected for structural correction or volume. Individual formulations vary.
Can skin boosters and dermal fillers be used together?
Potentially, where a patient has distinct treatment objectives and the combination forms part of an appropriately assessed and planned treatment pathway.
Are polynucleotides skin boosters?
They are often discussed alongside skin boosters commercially, but polynucleotide formulations are a distinct product category and should not automatically be treated as interchangeable with HA-based skin boosters.
Which is better: skin boosters or dermal fillers?
Neither category is universally better. The appropriate option depends on the patient’s anatomy, clinical presentation, treatment objective and the characteristics of the specific product being considered.
Skin Boosters vs Dermal Fillers: Key Takeaways
- Skin boosters and dermal fillers can both contain HA but should not be treated as interchangeable.
- Skin boosters are generally selected for skin-quality objectives; dermal fillers are commonly selected for product-dependent volume, contour and structural correction.
- The term “skin booster” covers products with substantially different formulations.
- Polynucleotides are an adjacent but distinct category.
- Product selection should follow patient assessment, individual formulation and current manufacturer guidance.
- Skin boosters and dermal fillers may form part of a staged plan when they address different objectives.
References and Further Practitioner Reading
- Current manufacturer product information and instructions for use for the individual product being considered.
- IBSA – Profhilo manufacturer information
- British College of Aesthetic Medicine – dermal filler information
- Longeva Pharma – Profhilo vs Dermal Fillers
- Longeva Pharma – Polynucleotides Practitioner Guide
Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharma is a GPhC-registered pharmacy (registration 9012378). Information is intended for UK practitioners and does not replace individual clinical judgement or current manufacturer product information.